Article citationsMore>>

Gertz, M.A., Comenzo, R., Falk, R.H., Fermand, J.P., Hazenberg, B.P., Hawkins, P.N., et al. (2005) Definition of Organ Involvement and Treatment Response in Immunoglobulin Light Chain Amyloidosis (AL): A Consensus Opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April. American Journal of Hematology, 79, 319-328.
https://doi.org/10.1002/ajh.20381

has been cited by the following article:

• TITLE: A Case Report of Cardiac Amyloidosis Presenting with Chest Discomfort

  AUTHORS: Binay Kumar Adhikari, Yonggang Wang, Bo Li, Quan Liu, Weihua Zhang

  KEYWORDS: Cardiac Amyloidosis, Cardiomyopathy, Heart Failure

  JOURNAL NAME: World Journal of Cardiovascular Diseases, Vol.8 No.2, February 13, 2018

  ABSTRACT: Introduction: Cardiac amyloidosis is one of the several systemic manifestations of amyloidosis. It is a relatively uncommon disease. Patients with cardiac amyloidosis clinically present with rapidly progressive heart failure. Case Presentation: We present a case of 64-year-old man with multiple episodes of chest discomfort accompanied sometimes with dyspnoea for the past several months. A non-specific ST-T changes with low voltage limb leads on ECG, a diastolic dysfunction with preserved ejection fraction on echocardiography, increased troponin and BNP, increased serum λ/κ light chain ratio led us to highly suspect amyloidosis with cardiac involvement. Abdominal fat pad biopsy confirmed the amyloid type change of subcutaneous fat, with immunohistochemistry revealing Lambda positive. After confirmed diagnosis of primary systemic amyloidosis with cardiac involvement, patient completed six cycles of chemotherapy with bortezomib and dexamethasone. The patient showed significant improvements after chemotherapy and supportive therapy. Conclusion: Amyloidosis is relatively fatal disease. Patients often have a short life expectancy after symptom onset. Early diagnosis is crucial to proper management and better prognosis.